Table 5. Metabolic syndrome prevalence and odds ratio's in four cross-sectional studies.
| Parameters | Nuveret al (2005) | Haugneset al (2007) | Wethalet al (2007) | this study | ||
|---|---|---|---|---|---|---|
| Number of survivors | 130 | 1135 | 589 | 251 | ||
| Mean age (years) (range) | 38.5 (20–65) | 42.5 (23–60) | 42 (23–60) | 39.6 (18–70) | ||
| Mean follow-up time (years) (range) | 7.5 (3–13) | 11.2 (5–22) | 11 (7.7–14.5) | 7.8 (0.1–30.0) | ||
| Healthy subjects (N) | 47 | 1150 | 8835 | 360 | ||
| Metabolic syndrome definition |
NCEP-ATP III |
Modified NCEP-ATP III ⩾ 2 criteriaa |
Modified NCEP-ATP III ⩾3 criteriaa |
Modified criteria ⩾3 criteriaa |
NCEP-ATP III |
IDF |
|
Metabolic syndrome prevalence (%) | ||||||
| All GCT survivors | 38 (29.2) | 447 (39.4) | 92 (8.1) | 82 (13.9) | 36 (14.3) | 66 (26.3) |
| Combination CT | 22 (25.6) | 191 (41.2) | 40 (8.6) | 38 (17.4) | 29 (16.7) | 52 (29.9) |
| Single-dose carboplatin | ∼ | ∼ | ∼ | ∼ | 2 (10.0) | 5 (25.0) |
| Radiotherapy | ∼ | 184 (42.0) | 37 (8.3) | 35 (15.2) | ∼ | ∼ |
| Surgery only | 16 (34.0) | 72 (33.0) | 15 (6.7) | 9 (6.4) | 5 (8.8) | 9 (15.8) |
| Healthy subjects |
4 (8.5) |
584 (51.5) |
170 (14.8) |
Not mentioned |
29 (8.1) |
59 (16.4) |
|
OR (95% CI) adjustmentsb | ||||||
| GCT survivors vs healthy subjects | 4.4 (1.5–13.2) | 0.6 (0.5–0.7) | 0.5 (0.4–0.7) | ∼ | 1.9 (1.1–3.2) | 1.8 (1.2–2.7) |
| Combination CT vs healthy subjects | 3.7 (1.2–11.5) | 0.7 (0.5–0.8) | 0.5 (0.4–0.8) | 3.7 (1.5–9.1) | 2.3 (1.3–4.0) | 2.2 (1.4–3.3) |
| Combination chemotherapy vs surgery only | 0.6 (0.3–1.3) | 1.5 (1.1–2.1) | 1.3 (0.7–2.4) | 3.1 (1.4–6.6) | 2.1 (0.8–5.7) | 2.3 (1.0–5.0) |
Abbreviations: CI=confidence interval; CT=chemotherapy; GCT=germ cell tumour; IDF=International Diabetes Federation; OR=Odds ratio; NCEP-ATPIII=National Cholesterol Education Program Adult Treatment Panel III 2001.
a
Non-fasting blood samples.
b
Calculated from the raw data presented in the individual reports.